Vigil Neuroscience (NASDAQ:VIGL) Stock Rating Reaffirmed by HC Wainwright

Vigil Neuroscience (NASDAQ:VIGL)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They currently have a $24.00 price target on the stock.

Several other equities analysts have also recently commented on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $23.00 price objective on shares of Vigil Neuroscience in a research note on Thursday, April 18th. Wedbush reaffirmed an “outperform” rating and set a $22.00 price objective on shares of Vigil Neuroscience in a research note on Wednesday, May 8th.

Vigil Neuroscience Stock Down 10.7 %

NASDAQ VIGL opened at $4.00 on Friday. The company’s 50 day moving average is $3.51 and its 200-day moving average is $3.32. The firm has a market cap of $150.32 million, a P/E ratio of -1.89 and a beta of 1.94. Vigil Neuroscience has a 12-month low of $2.47 and a 12-month high of $10.22.

Vigil Neuroscience (NASDAQ:VIGL) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.10. Equities analysts expect that Vigil Neuroscience will post -2.09 EPS for the current year.

Hedge Funds Weigh In On Vigil Neuroscience

A number of hedge funds and other institutional investors have recently bought and sold shares of VIGL. PEAK6 Investments LLC grew its stake in Vigil Neuroscience by 66.0% in the 3rd quarter. PEAK6 Investments LLC now owns 23,796 shares of the company’s stock worth $128,000 after buying an additional 9,459 shares in the last quarter. Strs Ohio purchased a new stake in shares of Vigil Neuroscience in the 4th quarter valued at $27,000. Finally, Vanguard Group Inc. boosted its stake in shares of Vigil Neuroscience by 11.9% in the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock valued at $3,050,000 after purchasing an additional 95,276 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.